Fella Health GLP-1 Pricing Review in 2026: Semaglutide, Tirzepatide, and Brand Access

The biggest reason Fella needs its own review page is that its public pricing page is really showing three distinct paths. The first is compounded semaglutide, the second is compounded tirzepatide, and the third is a branded Zepbound access plan tied to LillyDirect language.

That matters because some shoppers see the $149 branded number and assume it is just a cheaper branded medication price. It is not framed that way in the tracked data. The site treats it as a program-access price with medication billed separately, while the compounded options are more direct medication-centered offers.

At $99 per month for compounded semaglutide and $199 per month for compounded tirzepatide, Fella enters the market at a competitive level compared with many other telehealth-first providers. That puts it in the same general budget conversation as some other value-driven names in the directory, especially for users who are focused on cash-pay entry points.

The caveat is that the compounded prices are advertised monthly but billed annually. That changes the real checkout feel, even if the normalized monthly number is still useful for apples-to-apples comparison across the site.

The compounded offers carry the usual compounded-medication caution: they are not approved or evaluated by the FDA for safety, efficacy, or quality in the same way as branded drugs. The branded access path has a different caveat: the page language is less clean, and the visible ingredient labeling is not fully consistent with the Zepbound framing.

That does not make the page unusable. It just means Fella is a provider where reading the notes and disclaimers on the provider page is part of the real comparison process, especially if you are deciding between compounded and brand-linked pathways.